{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:47:39Z","timestamp":1781236059894,"version":"3.54.1"},"reference-count":62,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T00:00:00Z","timestamp":1621987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Foundation of Korea (NRF) funded by the Korean government","award":["NRF-2020R1A2C2014194 and NRF-2019R1A2C1006331"],"award-info":[{"award-number":["NRF-2020R1A2C2014194 and NRF-2019R1A2C1006331"]}]},{"name":"Bio & Medical Technology Development Program of the NRF funded by the Korean government, MSIP","award":["NRF-2020M3A9G3080282"],"award-info":[{"award-number":["NRF-2020M3A9G3080282"]}]},{"DOI":"10.13039\/501100010418","name":"Institute for Information and Communications Technology Promotion","doi-asserted-by":"publisher","award":["2019-0-00567"],"award-info":[{"award-number":["2019-0-00567"]}],"id":[{"id":"10.13039\/501100010418","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Skeletal muscle atrophy is a feature of aging (termed sarcopenia) and various diseases, such as cancer and kidney failure. Effective drug treatment options for muscle atrophy are lacking. The tapeworm medication, niclosamide is being assessed for repurposing to treat numerous diseases, including end-stage cancer metastasis and hepatic steatosis. In this study, we investigated the potential of niclosamide as a repurposing drug for muscle atrophy. In a myotube atrophy model using the glucocorticoid, dexamethasone, niclosamide did not prevent the reduction in myotube diameter or the decreased expression of phosphorylated FOXO3a, which upregulates the ubiquitin-proteasome pathway of muscle catabolism. Treatment of normal myotubes with niclosamide did not activate mTOR, a major regulator of muscle protein synthesis, and increased the expression of atrogin-1, which is induced in catabolic states. Niclosamide treatment also inhibited myogenesis in muscle precursor cells, enhanced the expression of myoblast markers<jats:italic>Pax7<\/jats:italic>and<jats:italic>Myf5<\/jats:italic>, and downregulated the expression of differentiation markers<jats:italic>MyoD<\/jats:italic>,<jats:italic>MyoG<\/jats:italic>and<jats:italic>Myh2<\/jats:italic>. In an animal model of muscle atrophy, niclosamide did not improve muscle mass, grip strength or muscle fiber cross-sectional area. Muscle atrophy is also feature of cancer cachexia. IC<jats:sub>50<\/jats:sub>analyses indicated that niclosamide was more cytotoxic for myoblasts than cancer cells. In addition, niclosamide did not suppress the induction of<jats:italic>iNOS<\/jats:italic>, a key mediator of atrophy, in an<jats:italic>in vitro<\/jats:italic>model of cancer cachexia and did not rescue myotube diameter. Overall, these results suggest that niclosamide may not be a suitable repurposing drug for glucocorticoid-induced skeletal muscle atrophy or cancer cachexia. Nevertheless, niclosamide may be employed as a compound to study mechanisms regulating myogenesis and catabolic pathways in skeletal muscle.<\/jats:p>","DOI":"10.1371\/journal.pone.0252135","type":"journal-article","created":{"date-parts":[[2021,5,26]],"date-time":"2021-05-26T17:53:17Z","timestamp":1622051597000},"page":"e0252135","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Investigation of niclosamide as a repurposing agent for skeletal muscle atrophy"],"prefix":"10.1371","volume":"16","author":[{"given":"Hyun-Jun","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hyung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seon-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Hoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Woon","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren R.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,5,26]]},"reference":[{"key":"pone.0252135.ref001","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1038\/d41586-018-02479-z","article-title":"Fighting the inevitability of ageing","volume":"555","author":"L. Drew","year":"2018","journal-title":"Nature"},{"key":"pone.0252135.ref002","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1093\/ageing\/afq034","article-title":"Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People","volume":"39","author":"A. J. Cruz-Jentoft","year":"2010","journal-title":"Age Ageing"},{"key":"pone.0252135.ref003","first-page":"93","article-title":"Economic Impact of Hospitalizations in US Adults with Sarcopenia","volume":"8","author":"S. Goates","year":"2019","journal-title":"J Frailty Aging"},{"key":"pone.0252135.ref004","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3945\/an.115.008367","article-title":"Nutritional supplements in support of resistance exercise to counter age-related sarcopenia","volume":"6","author":"S. M. Phillips","year":"2015","journal-title":"Adv Nutr"},{"key":"pone.0252135.ref005","first-page":"217","article-title":"Optimal management of sarcopenia","volume":"5","author":"L. A. Burton","year":"2010","journal-title":"Clinical interventions in aging"},{"key":"pone.0252135.ref006","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0167-5273(02)00235-8","article-title":"Cancer cachexia","volume":"85","author":"K. C. Fearon","year":"2002","journal-title":"Int J Cardiol"},{"key":"pone.0252135.ref007","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jphs.2019.04.005","article-title":"A novel strategy for treatment of cancer cachexia targeting xanthine oxidase in the brain","volume":"140","author":"M. Uzu","year":"2019","journal-title":"Journal of pharmacological sciences"},{"key":"pone.0252135.ref008","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/jcsm.12226","article-title":"The mitochondrial metabolic reprogramming agent trimetazidine as an \u2019exercise mimetic\u2019 in cachectic C26-bearing mice","volume":"8","author":"F. Molinari","year":"2017","journal-title":"Journal of cachexiasarcopenia and muscle"},{"key":"pone.0252135.ref009","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/jcsm.12054","article-title":"Salidroside alleviates cachexia symptoms in mouse models of cancer cachexia via activating mTOR signalling","volume":"7","author":"X. Chen","year":"2016","journal-title":"Journal of cachexiasarcopenia and muscle"},{"key":"pone.0252135.ref010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cellsig.2017.04.001","article-title":"Niclosamide: Beyond an antihelminthic drug","volume":"41","author":"W. Chen","year":"2018","journal-title":"Cell Signal"},{"key":"pone.0252135.ref011","doi-asserted-by":"crossref","first-page":"e0124595","DOI":"10.1371\/journal.pone.0124595","article-title":"Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus","volume":"10","author":"R. Rajamuthiah","year":"2015","journal-title":"PloS one"},{"key":"pone.0252135.ref012","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02185-18","article-title":"Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses","volume":"93","author":"C. E. Hulseberg","year":"2019","journal-title":"J Virol"},{"key":"pone.0252135.ref013","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1038\/nm.3699","article-title":"Niclosamide ethanolamine-induced mild mitochondrial uncoupling improves diabetic symptoms in mice","volume":"20","author":"H. Tao","year":"2014","journal-title":"Nature medicine"},{"key":"pone.0252135.ref014","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1007\/s00018-019-03134-0","article-title":"Drug repurposing to overcome resistance to various therapies for colorectal cancer. Cellular and molecular life sciences","volume":"76","author":"W. Fong","year":"2019","journal-title":"CMLS"},{"key":"pone.0252135.ref015","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","article-title":"JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia","volume":"303","author":"A. Bonetto","year":"2012","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"pone.0252135.ref016","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3389\/fnagi.2014.00230","article-title":"The intriguing regulators of muscle mass in sarcopenia and muscular dystrophy","volume":"6","author":"K. Sakuma","year":"2014","journal-title":"Front Aging Neurosci"},{"key":"pone.0252135.ref017","doi-asserted-by":"crossref","first-page":"82ra37","DOI":"10.1126\/scitranslmed.3002227","article-title":"Losartan restores skeletal muscle remodeling and protects against disuse atrophy in sarcopenia","volume":"3","author":"T. N. Burks","year":"2011","journal-title":"Science translational medicine"},{"key":"pone.0252135.ref018","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semcdb.2016.02.009","article-title":"STAT3 in the systemic inflammation of cancer cachexia","volume":"54","author":"T. A. Zimmers","year":"2016","journal-title":"Seminars in cell & developmental biology"},{"key":"pone.0252135.ref019","doi-asserted-by":"crossref","first-page":"E1417","DOI":"10.1152\/ajpendo.90567.2008","article-title":"Mechanism of attenuation of muscle protein degradation induced by tumor necrosis factor-alpha and angiotensin II by beta-hydroxy-beta-methylbutyrate","volume":"295","author":"H. L. Eley","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"pone.0252135.ref020","doi-asserted-by":"crossref","DOI":"10.1101\/pdb.prot087379","article-title":"Crystal Violet Assay for Determining Viability of Cultured Cells","volume":"2016","author":"M. Feoktistova","year":"2016","journal-title":"Cold Spring Harb Protoc"},{"key":"pone.0252135.ref021","doi-asserted-by":"crossref","first-page":"e28628","DOI":"10.1371\/journal.pone.0028628","article-title":"A method for the direct identification of differentiating muscle cells by a fluorescent mitochondrial dye","volume":"6","author":"T. Miyake","year":"2011","journal-title":"PloS one"},{"key":"pone.0252135.ref022","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5483\/BMBRep.2011.44.8.517","article-title":"Niclosamide induces mitochondria fragmentation and promotes both apoptotic and autophagic cell death","volume":"44","author":"S. J. Park","year":"2011","journal-title":"BMB Rep"},{"key":"pone.0252135.ref023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1242\/dmm.010389","article-title":"Cellular and molecular mechanisms of muscle atrophy","volume":"6","author":"P. Bonaldo","year":"2013","journal-title":"Dis Model Mech"},{"key":"pone.0252135.ref024","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s13539-012-0074-6","article-title":"Molecular and cellular mechanisms of skeletal muscle atrophy: an update","volume":"3","author":"A. Fanzani","year":"2012","journal-title":"Journal of cachexiasarcopenia and muscle"},{"key":"pone.0252135.ref025","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2014new mechanisms for old drugs","volume":"353","author":"T. Rhen","year":"2005","journal-title":"The New England journal of medicine"},{"key":"pone.0252135.ref026","doi-asserted-by":"crossref","first-page":"14440","DOI":"10.1073\/pnas.251541198","article-title":"Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy","volume":"98","author":"M. D. Gomes","year":"2001","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"pone.0252135.ref027","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1042\/bj2600377","article-title":"Regulation of protein synthesis and degradation in L8 myotubes. Effects of serum, insulin and insulin-like growth factors","volume":"260","author":"E. A. Gulve","year":"1989","journal-title":"Biochem J"},{"key":"pone.0252135.ref028","doi-asserted-by":"crossref","first-page":"E469","DOI":"10.1152\/ajpendo.00204.2014","article-title":"Skeletal muscle atrophy and the E3 ubiquitin ligases MuRF1 and MAFbx\/atrogin-1","volume":"307","author":"S. C. Bodine","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"pone.0252135.ref029","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fphys.2017.00788","article-title":"mTOR as a Key Regulator in Maintaining Skeletal Muscle Mass","volume":"8","author":"M. S. Yoon","year":"2017","journal-title":"Front Physiol"},{"key":"pone.0252135.ref030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.arr.2015.12.004","article-title":"Skeletal muscle regeneration and impact of aging and nutrition","volume":"26","author":"C. Domingues-Faria","year":"2016","journal-title":"Ageing Res Rev"},{"key":"pone.0252135.ref031","first-page":"127","article-title":"Satellite cells, the engines of muscle repair. Nature reviews","volume":"13","author":"Y. X. Wang","year":"2011","journal-title":"Molecular cell biology"},{"key":"pone.0252135.ref032","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/jcsm.12393","article-title":"Myricanol rescues dexamethasone-induced muscle dysfunction via a sirtuin 1-dependent mechanism","volume":"10","author":"S. Shen","year":"2019","journal-title":"Journal of cachexiasarcopenia and muscle"},{"key":"pone.0252135.ref033","doi-asserted-by":"crossref","first-page":"15201","DOI":"10.1038\/ncomms15201","article-title":"miR-29b contributes to multiple types of muscle atrophy","volume":"8","author":"J. Li","year":"2017","journal-title":"Nature communications"},{"key":"pone.0252135.ref034","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jcsm.12475","article-title":"Metastasis and cachexia: alongside in clinics, but not so in animal models","volume":"10","author":"R. Tomasin","year":"2019","journal-title":"Journal of cachexiasarcopenia and muscle"},{"key":"pone.0252135.ref035","doi-asserted-by":"crossref","first-page":"6533","DOI":"10.1128\/MCB.25.15.6533-6545.2005","article-title":"NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release","volume":"25","author":"S. Di Marco","year":"2005","journal-title":"Molecular and cellular biology"},{"key":"pone.0252135.ref036","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.ijpharm.2018.10.053","article-title":"Physostigmine-loaded liposomes for extended prophylaxis against nerve agent poisoning","volume":"553","author":"J. H. Park","year":"2018","journal-title":"Int J Pharm"},{"key":"pone.0252135.ref037","doi-asserted-by":"crossref","first-page":"98","DOI":"10.4235\/agmr.19.0028","article-title":"Pharmacological Interventions for Treatment of Sarcopenia: Current Status of Drug Development for Sarcopenia","volume":"23","author":"J. Y. Kwak","year":"2019","journal-title":"Annals of Geriatric Medicine and Research"},{"key":"pone.0252135.ref038","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1021\/ml3003082","article-title":"Discovery of O-Alkylamino Tethered Niclosamide Derivatives as Potent and Orally Bioavailable Anticancer Agents","volume":"4","author":"H. Chen","year":"2013","journal-title":"ACS medicinal chemistry letters"},{"key":"pone.0252135.ref039","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3109\/02652048.2015.1057251","article-title":"Significantly enhanced bioavailability of niclosamide through submicron lipid emulsions with or without PEG-lipid: a comparative study","volume":"32","author":"X. Zhang","year":"2015","journal-title":"J Microencapsul"},{"key":"pone.0252135.ref040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s40425-019-0733-7","article-title":"Niclosamide, an antihelmintic drug, enhances efficacy of PD-1\/PD-L1 immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"F. Luo","year":"2019","journal-title":"J Immunother Cancer"},{"key":"pone.0252135.ref041","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1021\/cb3003368","article-title":"Reawakening atlas: chemical approaches to repair or replace dysfunctional musculature","volume":"7","author":"D. W. Jung","year":"2012","journal-title":"ACS chemical biology"},{"key":"pone.0252135.ref042","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(99)00037-X","article-title":"Mechanisms and kinetics of liposome-cell interactions","volume":"40","author":"scedil Duzgune","year":"1999","journal-title":"Adv Drug Deliv Rev"},{"key":"pone.0252135.ref043","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.2174\/1871520619666190705120011","article-title":"Nanoliposomal Encapsulation Enhances In Vivo Anti-Tumor Activity of Niclosamide against Melanoma","volume":"19","author":"M. Hatamipour","year":"2019","journal-title":"Anticancer Agents Med Chem"},{"key":"pone.0252135.ref044","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0163-7258(82)90064-X","article-title":"The biology and toxicology of molluscicides, Bayluscide","volume":"19","author":"P. Andrews","year":"1982","journal-title":"Pharmacol Ther"},{"key":"pone.0252135.ref045","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1152\/physiol.00039.2014","article-title":"Mitochondria, muscle health, and exercise with advancing age","volume":"30","author":"H. N. Carter","year":"2015","journal-title":"Physiology"},{"key":"pone.0252135.ref046","doi-asserted-by":"crossref","first-page":"17530","DOI":"10.1074\/jbc.M112.359638","article-title":"Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling","volume":"287","author":"B. D. Fonseca","year":"2012","journal-title":"The Journal of biological chemistry"},{"key":"pone.0252135.ref047","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1128\/MCB.01180-14","article-title":"WNT\/beta-Catenin Signaling Regulates Multiple Steps of Myogenesis by Regulating Step-Specific Targets","volume":"35","author":"A. Suzuki","year":"2015","journal-title":"Molecular and cellular biology"},{"key":"pone.0252135.ref048","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1158\/0008-5472.CAN-10-3978","article-title":"Antihelminth compound niclosamide downregulates Wnt signaling and elicits antitumor responses in tumors with activating APC mutations","volume":"71","author":"T. Osada","year":"2011","journal-title":"Cancer research"},{"key":"pone.0252135.ref049","doi-asserted-by":"crossref","DOI":"10.1242\/dev.168351","article-title":"WNT\/beta-catenin signaling plays a crucial role in myoblast fusion through regulation of nephrin expression during development","volume":"145","author":"A. Suzuki","year":"2018","journal-title":"Development"},{"key":"pone.0252135.ref050","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1158\/1535-7163.MCT-13-0095","article-title":"Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer","volume":"12","author":"R. Li","year":"2013","journal-title":"Molecular cancer therapeutics"},{"key":"pone.0252135.ref051","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19082265","article-title":"STAT3 in Skeletal Muscle Function and Disorders","volume":"19","author":"E. Guadagnin","year":"2018","journal-title":"Int J Mol Sci"},{"key":"pone.0252135.ref052","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.cmet.2013.07.012","article-title":"Stat3 activation links a C\/EBPdelta to myostatin pathway to stimulate loss of muscle mass","volume":"18","author":"L. Zhang","year":"2013","journal-title":"Cell metabolism"},{"key":"pone.0252135.ref053","first-page":"171","article-title":"Signal transducer and activator of transcription 3 signaling as a potential target to treat muscle wasting diseases","volume":"19","author":"D. Sala","year":"2016","journal-title":"Current opinion in clinical nutrition and metabolic care"},{"key":"pone.0252135.ref054","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.bbrc.2008.11.123","article-title":"Dependence of dexamethasone-induced Akt\/FOXO1 signaling, upregulation of MAFbx, and protein catabolism upon the glucocorticoid receptor","volume":"378","author":"W. Zhao","year":"2009","journal-title":"Biochemical and biophysical research communications"},{"key":"pone.0252135.ref055","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(04)00211-4","article-title":"The IGF-1\/PI3K\/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors","volume":"14","author":"T. N. Stitt","year":"2004","journal-title":"Molecular cell"},{"key":"pone.0252135.ref056","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.21873\/anticanres.14082","article-title":"Antihelminthic Niclosamide Induces Autophagy and Delayed Apoptosis in Human Non-small Lung Cancer Cells In Vitro and In Vivo","volume":"40","author":"W. H. Chai","year":"2020","journal-title":"Anticancer research"},{"key":"pone.0252135.ref057","doi-asserted-by":"crossref","first-page":"e0184324","DOI":"10.1371\/journal.pone.0184324","article-title":"Niclosamide induces protein ubiquitination and inhibits multiple pro-survival signaling pathways in the human glioblastoma U-87 MG cell line","volume":"12","author":"B. Cheng","year":"2017","journal-title":"PloS one"},{"key":"pone.0252135.ref058","first-page":"440","article-title":"Niclosamide ethanolamine prevents muscle wasting by inhibiting p38 MAPK-FoxO3a activation in mice exposed to doxorubicin","volume":"13","author":"H. Zhan","journal-title":"International Journal of Clinical and Experimental Medicine"},{"key":"pone.0252135.ref059","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1159\/000373937","article-title":"SIRT1 suppresses doxorubicin-induced cardiotoxicity by regulating the oxidative stress and p38MAPK pathways","volume":"35","author":"Y. Ruan","year":"2015","journal-title":"Cell Physiol Biochem"},{"key":"pone.0252135.ref060","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1210\/endo.141.8.7621","article-title":"Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis","volume":"141","author":"J. R. Singleton","year":"2000","journal-title":"Endocrinology"},{"key":"pone.0252135.ref061","doi-asserted-by":"crossref","first-page":"113610","DOI":"10.1016\/j.bcp.2019.08.012","article-title":"Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway","volume":"169","author":"Y. Zhu","year":"2019","journal-title":"Biochemical pharmacology"},{"key":"pone.0252135.ref062","doi-asserted-by":"crossref","first-page":"86803","DOI":"10.18632\/oncotarget.13466","article-title":"Niclosamide and its analogs are potent inhibitors of Wnt\/beta-catenin, mTOR and STAT3 signaling in ovarian cancer","volume":"7","author":"R. C. Arend","year":"2016","journal-title":"Oncotarget"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0252135","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,31]],"date-time":"2024-08-31T16:15:39Z","timestamp":1725120939000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0252135"}},"subtitle":[],"editor":[{"given":"Atsushi","family":"Asakura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,26]]},"references-count":62,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5,26]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0252135","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,26]]}}}